Prophylaxis of medium and severe clinical forms of COVID-19 infection with aminodihydrophtalazindione sodium salt (Galavit®) in medical personnel working in the «red zone»

Abstract

Introduction. Nowadays the aspects of COVID-19 prophylaxis remain especially actual among medical personnel providing medical aid to patients with this disease, mainly because of high risk of contact with the pathogen. Aminodihydrophtalazindione sodium salt is one of promising drugs for providing such prophylaxis.

Aim. Studying the effectiveness of medium and severe clinical forms of COVID-19 prophylaxis with the drug mentioned among medical personnel working in the «red zone» under circumstances of high epidemiological risk of COVID-19.

Material and methods. The study is retrospective and observational. 250 participants are included in the study. Statistical analysis was conducted using Pearson’s χ2 test, Mann-Whitney (U-test, multiple linear regression for creating the mathematical model of medium and severe COVID-19 forms risk determination.

Results. Statistically significant lowering of the risk of medium and severe COVID-19 forms is shown for prophylaxis with sodium aminodihydrophtalazindione; no effect on PCR test result was shown, as well as on quantitative grade of immune response (IgG concentration). In mathematical model predicting medium and severe forms statistical significance was found for the fact of prophylaxis and the positive immunological test (with IgG concentration higher than the threshold), that confirms the fact of contact with SARS-CoV-2.

Conclusion. A statistically significant reduction of the risk of moderate and severe forms of COVID-19 development was shown during prophylaxis with the investigated drug.

Keywords:COVID-19; coronaviral infection; medical personnel; prophylaxy; sodium aminodihydrophtalazindione; Galavit®

Funding. The study had no sponsor support.

Conflict of interests. The authors declare no conflict of interests.

For citation: Kolesov S.V., Gorbatyuk D.S., Panteleyev A.A., Bernakevich A.I., Ukolov K.Yu. Prophylaxis of medium and severe clinical forms of COVID-19 infection with aminodihydrophtalazindione sodium salt (Galavit®) in medical personnel working in the «red zone». Immunologiya. 2020; 41 (6): 527-39. DOI: https://doi.org/10.33029/0206-4952-2020-41-6-527-539 (in Russian)

References

1. Fehr A.R., Perlman S. Coronaviruses: an overview of their replication and pathogenesis. In: Coronaviruses: Methods and Protocols. New York: Springer, 2015: 1–23.

2. Weiss S.R., Leibowitz J. Coronavirus pathogenesis. In: Advances in Virus Research. Academic Press, 2011: 85–164.

3. Chan J.F.W., Lau S.K.P., Woo P.C.Y. The emerging novel Middle East respiratory syndrome coronavirus: the «knowns» and «unknowns». J. Formos. Med. Assoc. 2013; 112: 372–81. DOI: https://doi.org/10.1016/j.jfma.2013.05.010

4. Zumla A., Chan J.F.W., Azhar E.I., Hui D.S.C., Yuen K.Y. Coronaviruses-drug discovery and therapeutic options. Nat. Rev. Drug Discov. 2016; 15: 327–47. DOI: https://doi.org/10.1038/nrd.2015.37

5. Raoult D., Zumla A., Locatelli F., Ippolito G., Kroemer G. Coronavirus infections: epidemiological, clinical and immunological features and hypotheses. Cell Stress. 2020; 4: 66–75. DOI: https://doi.org/10.15698/cst2020.04.216

6. Zhou F., Yu T., Du R., Fan G., Liu, Y., Liu Z. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; Mar 11. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3

7. Cheng Z.J., Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020; Feb 18. DOI: https://doi.org/10.1007/s15010-020-01401-y

8. Wu Z., McGoogan J. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; Feb 24. DOI: https://doi.org/10.1001/jama.2020.2648

9. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med. 2020; 382: 929–36. DOI: https://doi.org/10.1056/NEJMoa2001191

10. Lee P.I., Hu Y., Chen P., Huang Y., Hsueh P. Are children less susceptible to COVID-19? J. Microbiol. Immunol. Infect. 2020; Feb 25. DOI: https://doi.org/10.1016/j.jmii.2020.02.011

11. Huang W.H., Teng L.C., Yeh T.K., Chen Y.J., Lo W.J., Wu M.J. 2019 Novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan, China. J. Microbiol. Immunol. Infect. 2020; 53: 481–4. DOI: https://doi.org/10.1016/j.jmii.2020.02.009

12. Burke R.M., Midgley C.M., Dratch A., Fenstersheib M., Haupt T., Holshue M. Active monitoring of persons exposed to patients with confirmed COVID-19 – United States, January-February 2020. MMWR Morb. Mortal. Wkly Rep. 2020; 69 (9): 245–6. DOI: https://doi.org/10.15585/mmwr.mm6909e1

13. Mungroo M.R., Khan N.A., Siddiqui R. Novel coronavirus: current understanding of clinical features, diagnosis, pathogenesis, and treatment options. Pathogens. 2020; 9 (4): 297. DOI: https://doi.org/10.3390/pathogens9040297

14. Gao Z., Xu Y., Sun C., Wang X., Guo Y., Qiu S. A systematic review of asymptomatic infections with COVID-19 [Electronic resource]. J. Microbiol. Immunol. Infect. 2020; May 15. DOI: https://doi.org/10.1016/j.jmii.2020.05.001

15. Li H., Liu Z., Ge J. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. Cell. Mol. Med. 2020; 24: 6558–70. DOI: https://doi.org/10.1111/jcmm.15364

16. Liu J., Liu Y., Xiang P., Pu L., Xiong H. Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage. MedRxiv. 2020. DOI: https://doi.org/10.1186/s12967-020-02374-0

17. Cao Q., Chen Y.C., Chen C.L., Chiu C.H. SARS-CoV-2 infection in children: transmission dynamics and clinical characteristics. J. Formos. Med. Assoc. 2020; 119: 670–3. DOI: https://doi.org/10.1016/j.jfma.2020.02.009

18. Peiris J.S., Chu C.M., Cheng V.C., Chan K.S., Hung I.F., Poon L.L. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361: 1767–2. DOI: https://doi.org/10.1016/s0140-6736(03)13412-5

19. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 397: 507–13. DOI: https://doi.org/10.1016/S0140-6736(20)30211-7

20. Lee P.I., Hsueh P.R. Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J. Mcirobiol. Immunol. Infect. 2020; 53: 365–7. DOI: https://doi.org/10.1016/j.jmii.2020.02.001

21. Bokovikova T.N., Bagirova V.L., Сhernikova E.P. New drug Galavit: methods of analysis and standartization. Farmateka. 1999; (2): 53–5. (in Russian)

22. Latysheva T.V., Setdikova N.H., Man’ko K.S. Secondary immunodeficits. Possibilities of using new immunomodulator Galavit. Tsitokiny i vospalenie. 2005; 4 (3): 95–9. (in Russian)

23. Latysheva T.V., Shcherbakova O.V. Clinical aspects of using immunomodulatory drug Galavit, developed in Russia. Farmateka. 2004; 7: 51–4. (in Russian)

24. Rumyantsev A.G., Shcherbina A.Yu. Effectiveness of Galavit at treating children after 6 years of age with often and long-term infections. Rossiyskiy vestnik perinatologii i pediatrii. 2008; (6): 100–1. (in Russian)

25. Dyadina K.S., Zemskov A.M., Berezhnova T.A., Mihaylova M.D., Zemskova V.A., Dobrosotskikh G.V. Perspectives of immunotherapy of purulent diseases. Vestnik novykh meditsinskikh tekhnologiy. Elektronnoe izdanie. 2020; 2: 81–9. (in Russian)

26. Borshchuk E.L., Popov Yu.N., San’kov A.N. Analysis of immunomodulate drugs at pharmaceutical market. Izvestiya OGAU. 2016; 3: 218–21. (in Russian)

27. Luss L.V., Martynov-Radushinskiy A.A. Secondary immunodeficit. Do we need immunomodulatory drugs at all cases? Meditsinskiy sovet. 2014; 2: 40–5. (in Russian)

28. Sviridova S.P., Nekhaev I.V., Sytov A.V., Nikolaeva E.V., Blindar’ V.N., Borovkova N.V., Lomidze S.F., Klimanov I.A. Perioperative immunocorrection at the circumstances of hypercatabolism at oncological patients. Vestnik RONTs imeni N.N. Blohkina. 2008; 3: 51–6. (in Russian)

29. Korobkova L.I., Vel’sher L.Z., Germanov A.B., Grishina T.I., Stanulis A.I., Gene G.P., Shchepelyaev D.O., Izrailov R.E. Role of immunomodulatory drug Galavit in oncological and surgical practice. Rossiyskiy bioterapevticheskiy zhurnal. 2004; 3: 87–92. (in Russian)

30. Ciklauri V.T., Zabotina T.N., Korotkova O.V., Solov’ev S.S., Matyakin E.G., Kadagidze Z.G. Effect of Galavit at phagocytic activity of immune cells in oncological patients. Rossiyskiy bioterapevticheskiy zhurnal. 2012; 2: 61–5. (in Russian)

31. Sologub T.V., Osinovets O.Yu. Use of immunomodulatory drug Galavit in complex therapy of influenza. Klinitsist. 2012; 2: 76–80. (in Russian)

32. Temporary clinical guideline of Ministry of Health of Russian Federation: diagnosis and treatment of novel coronavirus infection (COVID-19). Ministry of Health of Russian Federation. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v8.pdf (date of access August 15, 2020) (in Russian)

33. Aleksandrovich Yu.S., Alekseeva E.I., Bakradze M.D., Baranov A.A., Batysheva T.T., Vashakmadze N.D., Vershinina M.G., Vishneva E.A., Glazyrina A.A., Gordeeva O.B., D’yakonova E.Yu., Zholobova E.S., Zabolotskiy D.V., Zvereva N.N., Zelenkova I.V., Ivanov D.O., Kaytukova E.V., Karkashadze G.A., Konovalov I.V., Kryuchko D.S., Kulichenko T.V., Kurbanova S.H., Levina Yu.G., Lobzin Yu.V., Mazankova L.N., Margieva T.V., Namazova-Baranova L.S., Novikova Yu.Yu., Ovsyannikov D.Yu., Petryaykina E.E., Petrenko Yu.V., Petrova N.V., Prometnoy D.V., Pshenisnov K.V., Revunenkov G.V., Rtishchev A.Yu., Rusinova D.S., Sayfullin M.A., Sayfullin R.F., Selimzyanova L.R., Tatochenko V.K., Tepaev R.F., Uskov A.N., Fedoseenko M.V., Fisenko A.P., Khar’kin A.V., Efendieva K.E., Yakovlev A.V. Aspects of clinical manifestation and treatment of COVID-19 disease in children. Version 2. Pediatricheskaya farmakologiya. 2020; 17 (3): 187–212. DOI: https://doi.org/10.15690/pf.v17i3.2123 (in Russian)

34. Sologub T.V., Osinovets O.Yu. Immunomodulatory drugs in complex therapy of acute respiratory viral infection: possibilities of use of Galavit. Russkiy meditsinskiy zhurnal. 2013; 2 (3): 144–6. (in Russian)

35. Sologub T.V., Semenyako N.A. New possibilities of antiviral therapy of chronic C hepatitis with including of immunomodulatory drug Galavit, developed in Russia. Vestnik Sankt-Peterburgskoy gosudarstvennoy meditsinskoy akademii imeni I.I. Mechnikova. 2009; 1 (30): 167–71. (in Russian)

36. Grishina T.N., Kuz’mina E.G., Zahkarova N.S. Immunomodulatory abilities of Galavit (clinical use and effect mechanisms). In: Collected Papers «Galavit». 2002: 6–15. (in Russian)

37. Latysheva T.V., Shcherbakova O.A. New possibilities of target immunological correction at the example of immunomodulatory drug Galavit, developed in Russia. Rossiyskiy allergologicheskiy zhurnal. 2004; 1: 77–81. (in Russian)

38. Pashchenkov M.V., Khaitov M.R. Immune response against epidemical coronaviruses. Immunologiya. 2020; 41 (1): 5–18. DOI: https://doi.org/10.33029/0206-4952-2020-41-1-5-18 (in Russian)

39. Namazova-Baranova L.S., Baranov A.A. COVID-19 coronaviral infection in children: state at the time of June 2020). Pediatricheskaya farmakologiya. 2020; 17 (3). DOI: https://doi.org/10.15690/pf.v17i3.2121 (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)


JOURNALS of «GEOTAR-Media»